The combination of pembrolizumab, lenvatinib, and HAIC resulted in a median PFS of 10.9 months and a median OS of 17.7 months in patients with histologically PD-L1-positive HCC [146]. This evidence concerns the gene CD274 and hepatocellular carcinoma.